Malignant pleural mesothelioma is a rare and deadly cancer mainly caused by asbestos exposure. It is hard to surgically remove and is very aggressive, which makes it hard to treat. A trial known as the MARS 2 trial investigated to see if pleurectomy and decortication could improve the quality of[…]
From the blog
Surgery is Beneficial for Mesothelioma Patients
Pleural mesothelioma is a cancer mainly caused by asbestos exposure. It is a cancer of the pleura, which is a lining of the lungs. The outlook for the disease is poor, with a typical survival time after diagnosis being 9 to 20 months. The overall five-year survival rate is five[…]
Artificial Intelligence and Robotics Improving Mesothelioma Care
Patient care is improving thanks to artificial intelligence and robotics. One country leading the charge in using technology for healthcare is Vietnam. A study from the Cureus Journal of Medical Sciences looks at AI and robotics improving in Vietnam and how they can help mesothelioma patients in the future. AI[…]
Changes to Staging System for Mesothelioma
Malignant pleural mesothelioma is a rare cancer associated with asbestos exposure. Two very important aspects of treating mesothelioma are classification and staging. They are important because they guide treatment and predict outcomes. One system to classify cancers is the TNM system which was created by the IASLC. It classifies cancers[…]
Pleural Therapies Can Help Pleural Mesothelioma Patients
Malignant mesothelioma is a cancer of the mesothelium, which is the lining of certain areas of the body including the lungs (called the pleura). It is mainly caused by asbestos, and usually occurs 30 to 50 years after initial asbestos exposure. Mesothelioma has a poor outlook, with most patients living[…]
A Phase 1 Study to Investigate 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects (8479217)
The aims of this Study are to determine:
How much of the Study Drug (bemcentinib) ends up in urine and faeces
How much of the Study Drug and its breakdown products get into the bloodstream
The breakdown products (metabolites) of the Study Drug
The safety of the Study Drug and any side effects that might be associated with it.
Multimodal Therapy Helps Improve Survival in Mesothelioma Patients
Malignant pleural mesothelioma is an aggressive cancer mainly caused by asbestos exposure. It is a cancer of the mesothelium, which is the lining of certain areas of the body including the lungs. The cancer is aggressive and hard to treat. There is hope though in new surgical and therapy methods.[…]
Ga-68 FAPI PET Before Immunotherapy (FAPBI)
It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.
Pleural Mesothelioma Study Recruitment Challenges
Pleural mesothelioma is a cancer of the lining of the lungs called the mesothelium. It is both rare and aggressive and is linked to asbestos exposure. Patient survival is poor and there are limited treatment options for this cancer. A new study known as MARS 2 looked at surgery alongside[…]
A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001)
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with pembrolizumab in patients with solid tumors (STEALTH-001).
